Cost-effectiveness analysis of dostarlimab plus carboplatin-paclitaxel as first-line treatment for advanced endometrial cancer

BACKGROUND: A recent phase III clinical trial (NCT03981796) evaluated the efficacy and safety of dostarlimab combined with carboplatin-paclitaxel (DOS-CP) compared to placebo combined with carboplatin-paclitaxel (PLB-CP) as a first-line treatment for advanced endometrial cancer (EC). The NCT03981796...

Descripción completa

Detalles Bibliográficos
Autores principales: You, Maojin, Zeng, Xiaoling, Zhang, Jinrong, Huang, Yufan, Zhang, Yalan, Cai, Zhongjie, Hu, Yingying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507332/
https://www.ncbi.nlm.nih.gov/pubmed/37731489
http://dx.doi.org/10.3389/fimmu.2023.1267322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507332/
https://www.ncbi.nlm.nih.gov/pubmed/37731489
http://dx.doi.org/10.3389/fimmu.2023.1267322

Ejemplares similares